A detailed history of Macquarie Group LTD transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 76,601 shares of JANX stock, worth $3.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,601
Previous 76,601 -0.0%
Holding current value
$3.85 Million
Previous $3.21 Million 8.45%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$35.12 - $64.78 $583,027 - $1.08 Million
16,601 Added 27.67%
76,601 $3.21 Million
Q1 2024

May 14, 2024

BUY
$7.93 - $49.75 $475,800 - $2.99 Million
60,000 New
60,000 $2.26 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.1B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.